Teratogenic effects of first-trimester cyclophosphamide therapy

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Teratology

Background:

• Systemic lupus erythematosus (SLE) exacerbations can be severe and require potent immunosuppressive therapy.
• Cyclophosphamide is a commonly used cytotoxic agent for managing severe autoimmune diseases.
• Pregnancy status must be carefully assessed before administering potentially teratogenic medications.

Observation:

• A pregnant patient in her first trimester, unaware of her condition, received intravenous cyclophosphamide for a severe SLE flare.
• The patient was concurrently treated with prednisone.
• The neonate presented with multiple congenital anomalies, including limb defects (absent thumbs), craniofacial abnormalities (cleft palate, low-set ears), and ocular abnormalities.

Findings:

• The observed congenital anomalies in the neonate are consistent with the known teratogenic effects of cyclophosphamide.
• This case provides clinical evidence linking first-trimester cyclophosphamide exposure to severe fetal malformations.
• The teratogenic potential of cyclophosphamide necessitates extreme caution during early gestation.

Implications:

• Clinicians must exercise stringent judgment regarding cyclophosphamide use in women of reproductive age, especially during the first trimester.
• Effective contraception and regular pregnancy testing are crucial for nonpregnant women of childbearing potential receiving potentially teratogenic medications.
• This case underscores the importance of comprehensive risk-benefit assessments and patient counseling regarding drug safety in pregnancy.